ArticleCureus2025
Vaginal Myeloid Sarcoma: A Rare Extramedullary Presentation of a Myeloid Neoplasm.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma is a rare extramedullary tumor often associated with acute myeloid leukemia (AML), but it can also appear as an isolated lesion. Vaginal involvement is extremely rare and may lead to delayed diagnosis due to nonspecific symptoms. We report a 41-year-old woman with a history of two cesarean sections who presented with dyspareunia. A firm, fixed mass was palpated on the posterior vaginal wall. Transvaginal ultrasonography and pelvic MRI revealed a 7.5 × 4.3 cm mass in the rectovaginal space without rectal infiltration. The lesion was excised vaginally, and intraoperative endoscopy confirmed rectal integrity. Histopathology showed blast cell infiltration with strong CD7, CD38, CD43, CD45, and BCL-2 positivity, consistent with myeloid sarcoma. Bone marrow biopsy confirmed AML. The patient was treated with 16 cycles of chemotherapy and underwent allogeneic bone marrow transplantation. This case illustrates the diagnostic challenge of vaginal myeloid sarcoma and emphasizes the role of imaging, immunohistochemistry, and multidisciplinary management in such rare presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.